Page last updated: 2024-11-04

phosphoenolpyruvate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphoenolpyruvate: A monocarboxylic acid anion derived from selective deprotonation of the carboxy group of phosphoenolpyruvic acid. It is a metabolic intermediate in GLYCOLYSIS; GLUCONEOGENESIS; and other pathways. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phosphoenolpyruvate : A monocarboxylic acid anion resuting from selective deprotonation of the carboxy group of phosphoenolpyruvic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

phosphoenolpyruvic acid : A monocarboxylic acid that is acrylic acid substituted by a phosphonooxy group at position 2. It is a metabolic intermediate in pathways like glycolysis and gluconeogenesis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1005
CHEMBL ID1235228
CHEBI ID44897
SCHEMBL ID7908
MeSH IDM0016661

Synonyms (37)

Synonym
oxo-phosphonooxy-acetic acid
CHEMBL1235228
2-(phosphonooxy)-2-propenoate
2-phosphonooxyprop-2-enoic acid
p-enol-pyruvate
phosphoenolpyruvic acid
PEP ,
C00074
phosphoenolpyruvate
138-08-9
2-phosphoenolpyruvic acid
CHEBI:44897 ,
2-(phosphonooxy)-2-propenoic acid
2-(phosphonooxy)prop-2-enoic acid
1NHX
DB01819
C39259BA-D4B1-4B31-810F-E572F40F427F
p-enolpyruvate
BMSE000107
phosphopyruvic acid
acrylic acid, 2-hydroxy-, dihydrogen phosphate
unii-545yl308ow
2-dihydroxyphosphinoyloxyacrylic acid
545yl308ow ,
2-propenoic acid, 2-(phosphonooxy)-
einecs 205-312-2
bdbm50366413
gtpl4692
SCHEMBL7908
phospho(enol)pyruvic acid
AKOS028109883
2-hydroxy-acrylic acid dihydrogen phosphate
DTXSID80861797
Q412139
EN300-260208
CS-0059436
2-(phosphonooxy)prop-2-enoicacid

Research Excerpts

Overview

Phosphoenolpyruvate (PEP) is a precursor involved in the biosynthesis of aromatics and other valuable compounds in Escherichia coli. It is an intermediate metabolite of the glycolytic pathway and an in vivo high-energy phosphate compound.

ExcerptReferenceRelevance
"Phosphoenolpyruvate acts as a weak inhibitor of the enzyme."( Biochemical characterisation of triose phosphate isomerase from the liver fluke Fasciola hepatica.
Hoey, EM; Timson, DJ; Trudgett, A; Zinsser, VL, 2013
)
1.11
"Phosphoenolpyruvate (PEP) is a precursor involved in the biosynthesis of aromatics and other valuable compounds in Escherichia coli. "( Physiological and transcriptional characterization of Escherichia coli strains lacking interconversion of phosphoenolpyruvate and pyruvate when glucose and acetate are coutilized.
Bolívar, F; Flores, N; Gosset, G; Hernández-Chávez, G; Sabido, A; Sigala, JC, 2014
)
2.06
"Phosphoenolpyruvate (PEP) is an intermediate metabolite of the glycolytic pathway and an in vivo high-energy phosphate compound. "( Phosphoenolpyruvate administration protects ischemia-reperfusion injury in isolated rabbit lungs.
Funaki, K; Inagaki, Y; Minami, Y; Mochida, S; Moriyama, N; Oshima, Y; Otsuki, A; Sakamoto, S; Yamasaki, K, 2015
)
3.3
"Phosphoenolpyruvate also acts as a precursor for the synthesis of aromatic amino acids in plastids."( Antisense inhibition of enolase strongly limits the metabolism of aromatic amino acids, but has only minor effects on respiration in leaves of transgenic tobacco plants.
Börnke, F; Czogalla-Peter, C; Hajirezaei, MR; Lein, W; Sonnewald, U; Stitt, M; Voll, LM, 2009
)
1.07
"The phosphoenolpyruvate (PEP) node is an important carbon distribution point in the central metabolic networks; therefore, its modification is a common strategy employed for developing microbial production strains. "( Physiologic consequences of glucose transport and phosphoenolpyruvate node modifications in Bacillus subtilis 168.
Bolívar, F; Cabrera-Valladares, N; Flores, N; Gosset, G; Hernández-Chávez, G; Martínez, A; Martínez, LM, 2012
)
1.19
"Phosphoenolpyruvate (PEP) is an endogenous substance that is one of the ATP precursors and can cross some cell membranes via anion exchanger."( Preventive effect of phosphoenolpyruvate on hypoxemia induced by oleic acid in Guinea pigs.
Golbidi, S; Hamasaki, N; Irie, T; Irikura, M; Moriuchi, H; Yang, C, 2003
)
1.36
"Phosphoenolpyruvate (PEP) is a phosphorylated glycolytic intermediate that can penetrate the RBC membrane and be metabolized to 2,3-DPG and ATP. "( Application of phosphoenolpyruvate into canine red blood cell cryopreservation with hydroxyethyl starch.
Itamoto, K; Kim, H; Nakaichi, M; Sumida, S; Taura, Y; Une, S,
)
1.93
"Phosphoenolpyruvate (PEP) is a glycolytic substrate which can be metabolized to pyruvate with concomitant formation of ATP. "( [Augmentation of hypoxic pulmonary vasoconstriction in isolated rabbit lungs with phosphoenolpyruvate].
Okazaki, N; Oshima, Y, 2005
)
2
"Phosphoenolpyruvate (PEP) is a high-energy metabolite in the final step of glycolysis. "( Phosphoenolpyruvate prevents the decline in hepatic ATP and energy charge after ischemia and reperfusion injury in rats.
Chijiiwa, K; Hamasaki, N; Saiki, S; Shimizu, S; Tanaka, M; Yamaguchi, K, 1997
)
3.18
"Phosphoenolpyruvate is a promising component to prepare red blood cells having a higher oxygen-delivering capacity."( Red blood cell function and blood storage.
Hamasaki, N; Yamamoto, M, 2000
)
1.03
"Phosphoenolpyruvate (PEP) is a potent inhibitor of muscle creatine kinase. "( [Effect of phosphoenolpyruvate on creatine kinase activity in rabbit muscles].
Chetverikova, EP; Rozanova, NA,
)
1.96

Effects

Phosphoenolpyruvate (PEP) has been suggested to function as a signal molecule for the latter control system.

ExcerptReferenceRelevance
"Phosphoenolpyruvate carboxykinase has been implicated by Rognstad (Rognstad, R. "( Catecholamine stimulation of hepatic gluconeogenesis at the site between pyruvate and phosphoenolpyruvate.
Lardy, HA; Ochs, RS, 1983
)
1.93
"Phosphoenolpyruvate (PEP) has been suggested to function as a signal molecule for the latter control system."( Regulation of autotrophic metabolism in Pseudomonas oxalaticus OX1 wild-type and an isocitrate-lyase-deficient mutant.
Dijkhuizen, L; Meijer, WG, 1988
)
1
"Phosphoenolpyruvate carboxykinase has been purified from homogenates of Ascaris suum muscle strips to apparent homogeneity as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. "( Purification and characterization of phosphoenolpyruvate carboxykinase from the parasitic helminth Ascaris suum.
Nowak, T; Rohrer, SP; Saz, HJ, 1986
)
1.99

Treatment

ExcerptReferenceRelevance
"Phosphoenolpyruvate-treated blood provides increased oxygen consumption at a similar hematocrit when compared with untreated banked blood."( Transfusion of phosphoenolpyruvate-treated blood increases oxygen consumption in acute hemorrhage.
Bandy, WC; Cornum, RL; Martin, RR, 1998
)
1.37

Dosage Studied

ExcerptRelevanceReference
"The platelet-activating factor (PAF) produced by mouse embryos showed similar kinetics of action and dose-response curve, in a bioassay, as did 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine (PAF-acether)."( Partial characterization of the embryo-derived platelet-activating factor in mice.
O'Neill, C, 1985
)
0.27
"When an enzyme exhibits a high affinity for an inhibitor, the steady-state analysis of the mechanism is complicated by the non-linearity of normal dose-response plots or of reciprocal replots."( A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors.
Henderson, PJ, 1972
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
carboxyalkyl phosphate
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (78)

PathwayProteinsCompounds
Glycolysis1423
Pyruvate Metabolism2139
Gluconeogenesis2232
Amino Sugar Metabolism1731
Leigh Syndrome2139
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)2139
Pyruvate Dehydrogenase Complex Deficiency2139
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
Tay-Sachs Disease1731
Glycogenosis, Type VII. Tarui Disease1423
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Primary Hyperoxaluria II, PH22139
Pyruvate Kinase Deficiency2139
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Fanconi-Bickel Syndrome1423
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
Glycolysis and Pyruvate Dehydrogenase2428
D-Glucarate and D-Galactarate Degradation1022
Chorismate Biosynthesis1017
Gluconeogenesis from L-Malic Acid2024
Lipopolysaccharide Biosynthesis4153
Amino Sugar and Nucleotide Sugar Metabolism I1733
Peptidoglycan Biosynthesis I3036
Fructose Metabolism1520
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
Secondary Metabolites: Shikimate Pathway811
Lipopolysaccharide Biosynthesis II4053
Lipopolysaccharide Biosynthesis III3352
Peptidoglycan Biosynthesis II3037
Glycolysis I1023
Ethanol Fermentation1527
Glutamine Metabolism2225
Shikimate Pathway (Chorismate Biosynthesis)716
CMP-3-Deoxy-D-Manno-Octulosonate (CMP-Kdo) Biosynthesis411
Aminosugars metabolism ( Aminosugars metabolism )1529
D-Glycerate 2-phosphate = Phosphoenol-pyruvic acid + H2O ( Glycolysis and Gluconeogenesis )33
Citrate cycle ( Citrate cycle )2129
GTP + Oxaloacetic acid = GDP + Phosphoenol-pyruvic acid + CO2 ( Citrate cycle )25
Glycolysis and Gluconeogenesis ( Glycolysis and Gluconeogenesis )2718
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Aerobic glycolysis020
Citrate Cycle1930
Metabolic Epileptic Disorders2589
succinic fermentation pathway012
superpathway of central carbon metabolism346
respiration (anaerobic)026
glycolysis I118
superpathway of glycolysis, pyruvate dehydrogenase and TCA cycle134
sucrose degradation to ethanol and lactate (anaerobic)028
superpathway of glyoxylate cycle024
superpathway of glycolysis and Entner-Doudoroff023
glycolysis II017
glycolysis III018
peptidoglycan and lipid A precursor biosynthesis034
UDP-N-acetylmuramoyl-pentapeptide biosynthesis III (meso-DAP-containing)020
CMP-KDO biosynthesis I010
Isoprenoid precursor biosynthesis in Pf apicoplasts012
Central carbon metabolism019
Hexoses metabolism in proximal tubules016
Primary carbon metabolism2330
AtMetExpress overview0109
TCA cycle and deficiency of pyruvate dehydrogenase complex (PDHc)015
Metabolism overview078
Biochemical pathways: part I0466
Amino acid metabolism094
Metabolic reprogramming in colon cancer029
Glycolysis and gluconeogenesis017
Effect of L-carnitine on metabolism09

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, phosphoenolpyruvate carboxykinase, cytosolicHomo sapiens (human)IC50 (µMol)2.11002.11002.11002.1100AID977608
Chain A, Phosphoenolpyruvate Carboxykinase, CytosolicHomo sapiens (human)IC50 (µMol)2.11002.11002.11002.1100AID977608
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)Ki13,000.00000.02300.07000.1490AID681570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nucleoside diphosphate kinase activityPhosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolPhosphoenolpyruvate carboxykinase, cytosolic [GTP]Rattus norvegicus (Norway rat)
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID681570TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells2002American journal of physiology. Renal physiology, Jun, Volume: 282, Issue:6
Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT.
AID1802647PEPCK Inhibition Assay from Article 10.1021/acs.biochem.7b00178: \\Asymmetric Anchoring Is Required for Efficient O-Loop Opening and Closing in Cytosolic Phosphoenolpyruvate Carboxykinase.\\2017Biochemistry, 04-18, Volume: 56, Issue:15
Asymmetric Anchoring Is Required for Efficient Ω-Loop Opening and Closing in Cytosolic Phosphoenolpyruvate Carboxykinase.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
X-ray structures of two xanthine inhibitors bound to PEPCK and N-3 modifications of substituted 1,8-dibenzylxanthines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,938)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901181 (60.94)18.7374
1990's242 (12.49)18.2507
2000's235 (12.13)29.6817
2010's205 (10.58)24.3611
2020's75 (3.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 116.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index116.99 (24.57)
Research Supply Index7.61 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index219.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (116.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.05%)5.53%
Reviews69 (3.43%)6.00%
Case Studies10 (0.50%)4.05%
Observational0 (0.00%)0.25%
Other1,931 (96.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]